| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919050 | BAYER HLTHCARE | Compositions comprising azelastine |
Nov, 2025
(2 years from now) | |
| US8518919 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(2 years from now) | |
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Astepro Allergy is owned by Bayer Hlthcare.
Astepro Allergy contains Azelastine Hydrochloride.
Astepro Allergy has a total of 3 drug patents out of which 0 drug patents have expired.
Astepro Allergy was authorised for market use on 17 June, 2021.
Astepro Allergy is available in spray, metered;nasal dosage forms.
Astepro Allergy can be used as otc use: allergy symptom reliever; temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose.
The generics of Astepro Allergy are possible to be released after 04 June, 2028.
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose
Dosage: SPRAY, METERED;NASAL
ASTEPRO ALLERGY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic